Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis E Hruby

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Journal of Virology|August 22, 2008
Identification of a broad-spectrum arenavirus entry inhibitorRyan A Larson, Dongcheng Dai, Virginia T Hosack, et al.
Antiviral Research|May 16, 2008
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit modelAysegul Nalca, Josh M Hatkin, Nicole L Garza, et al.
Infection and Immunity|March 24, 2005
Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccineKaren L Kotloff, Steven S Wasserman, Kevin F Jones, et al.
Journal of Computer-Aided Molecular Design|October 26, 2007
Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approachesVsevolod Katritch, Chelsea M Byrd, Vladimir Tseitin, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2006
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in miceDebra C Quenelle, R M L Buller, Scott Parker, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrappingSophie Duraffour, María M Lorenzo, Gudrun Zöller, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxvirusesDebra C Quenelle, Mark N Prichard, Kathy A Keith, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient miceDouglas W Grosenbach, Aklile Berhanu, David S King, et al.
Plos One|May 3, 2013
Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infectionAdams Amantana, Yali Chen, Shanthakumar R Tyavanagimatt, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2013
Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virusJames R Burgeson, Dima N Gharaibeh, Amy L Moore, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Journal of Virology|August 22, 2008
Identification of a broad-spectrum arenavirus entry inhibitorRyan A Larson, Dongcheng Dai, Virginia T Hosack, et al.
Antiviral Research|May 16, 2008
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit modelAysegul Nalca, Josh M Hatkin, Nicole L Garza, et al.
Infection and Immunity|March 24, 2005
Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccineKaren L Kotloff, Steven S Wasserman, Kevin F Jones, et al.
Journal of Computer-Aided Molecular Design|October 26, 2007
Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approachesVsevolod Katritch, Chelsea M Byrd, Vladimir Tseitin, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2006
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in miceDebra C Quenelle, R M L Buller, Scott Parker, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2015
ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrappingSophie Duraffour, María M Lorenzo, Gudrun Zöller, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxvirusesDebra C Quenelle, Mark N Prichard, Kathy A Keith, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient miceDouglas W Grosenbach, Aklile Berhanu, David S King, et al.
Plos One|May 3, 2013
Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infectionAdams Amantana, Yali Chen, Shanthakumar R Tyavanagimatt, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2013
Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virusJames R Burgeson, Dima N Gharaibeh, Amy L Moore, et al.
Pageof 9